Skip to main content

Table 1 Baseline characteristics pre- and post-matching

From: Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison

Baseline characteristics a RADIANT-3 study sample A6181111
Pre-match Post-match As reported
Median age (years)b 58.0 56.5 56.5
Age > 64 years 27.4 26.3 26.3
Female 44.9 52.0 52.0
WHO or ECOGc performance status of 0 68.8d 55.0 55.0
Time since diagnosis ≥3 years 46.7 48.0 48.0
Number of disease sites    
1 28.2 31.4 31.4
2 36.8 33.7 33.7
≥3 35.0 34.9 34.9
Presence of distant metastases 96.2 94.7 94.7
Previous somatostatin analogues 49.2d 36.3 36.3
Previous systemic chemotherapy 48.7d 69.0 69.0
  1. Notes:
  2. aReported as percentages, unless otherwise noted.
  3. bFor A6181111, 56.5 is the midpoint between reported medians on the active (56) and placebo (57) arms.
  4. cAn ECOG performance status of 0 was equated to a WHO performance status of 0.
  5. d P < 0.05 for comparison vs. A6181111.